secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0000950170-22-002316
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro FY2021 revenue $61.9M, operating expenses $160.4M; cash $229.5M; Tasly payment at risk
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $229.5M at Dec 31, 2021, down from $326.5M; runway into H2 2023.
- Revenue $61.9M (up 45% from $42.7M) from Merck, BMS, EMD Serono collaborations.
- Operating expenses $160.4M (up 41% from $113.8M); R&D $104.4M, G&A $56.0M.
- STRO-002 Phase 1 dose-expansion enrollment completed Nov 2021; registrational study discussions expected mid-2022.
- Tasly seeks to renegotiate STRO-002 Greater China terms; $40M initial payment uncertain; Sutro considering remedies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022002316/0000950170-22-002316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022002316/stro-20220228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer